Holen Sie sich die Stockscreener-App
19.52
2.25%
0.43
Handel nachbörslich:
19.91
0.39
+2.00%
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Value Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 3000E Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Microcap Index - marketscreener.com
SGP Forecast — Price Target — Prediction for 2027 - TradingView
Transcript : SpyGlass Pharma, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP) - TradingView
Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to book forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to earnings forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to EBIT forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Fails to Dampen Investor OptimismRevenue Miss Report - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index - marketscreener.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SpyGlass Taps Shannon Treviño as General Counsel - Orange County Business Journal
SpyGlass Pharma appoints Shannon Treviño as general counsel to support Phase 3 trials and commercialization plans. - Pluang
SpyGlass Pharma appoints Shannon Treviño as general counsel By Investing.com - Investing.com Nigeria
SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General Counsel - marketscreener.com
SpyGlass Pharma appoints Shannon Treviño as general counsel - Investing.com
SpyGlass Pharma Appoints Shannon Treviño as General Counsel - GlobeNewswire
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesAnnual Report - dars.gov.et
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing - VisionMonday.com
SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com - Investing.com South Africa
SpyGlass Pharma appoints Mike Pinder as VP of marketing - Investing.com
SpyGlass Pharma (SGP) Slides 2.29% as Stock Approaches Critical Support at $17.0Liquidity Sweep - dars.gov.et
SGP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesCapex Guidance - dars.gov.et
SGPSpyGlass Pharma Inc Stock Price and Quote - Finviz
SpyGlass Pharma to Participate in Upcoming Investor Conferences - Sahm
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System - GlobeNewswire
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):